Alliancebernstein L.P. Raises Holdings in Zoetis Inc. $ZTS

Alliancebernstein L.P. boosted its stake in Zoetis Inc. (NYSE:ZTS) by 13.3% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,241,357 shares of the company’s stock after buying an additional 496,320 shares during the quarter. Alliancebernstein L.P. owned approximately 0.96% of Zoetis worth $620,595,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the stock. Halbert Hargrove Global Advisors LLC increased its position in Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after buying an additional 144 shares in the last quarter. Financial Consulate Inc. purchased a new stake in shares of Zoetis in the third quarter valued at $39,000. SJS Investment Consulting Inc. lifted its position in shares of Zoetis by 1,606.3% in the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock valued at $40,000 after acquiring an additional 257 shares in the last quarter. TruNorth Capital Management LLC acquired a new stake in shares of Zoetis during the third quarter valued at $42,000. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Zoetis during the third quarter valued at $46,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Ratings Changes

ZTS has been the subject of a number of recent research reports. Barclays began coverage on Zoetis in a research report on Monday, December 8th. They set an “equal weight” rating and a $136.00 price objective for the company. Morgan Stanley set a $160.00 price target on shares of Zoetis in a research note on Thursday, December 18th. Piper Sandler reiterated a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Stifel Nicolaus cut their price objective on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research report on Tuesday, November 18th. Finally, HSBC set a $140.00 price objective on shares of Zoetis in a research note on Wednesday, December 10th. Six investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $152.91.

Zoetis Stock Performance

Zoetis stock opened at $115.62 on Friday. The firm has a market capitalization of $48.81 billion, a P/E ratio of 19.21, a PEG ratio of 1.76 and a beta of 0.95. The stock has a fifty day moving average price of $125.34 and a 200 day moving average price of $131.75. Zoetis Inc. has a 52 week low of $114.47 and a 52 week high of $172.23. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. During the same period in the prior year, the business posted $1.40 earnings per share. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio is presently 35.22%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.